…through intimal thickening. DES release antiproliferative and anti inflammatory agents from the stent surface and have substantially reduced this process compared with BMS. Neoatherosclerosis Neoatherosclerosis…

…25–50 per cent and titrate. At a high dose, in old age or in renal failure, reduce it further. Starting doses in acute pain…

…and increased short and long term adverse cardiovascular outcomes. Clinical Presentation and Symptoms Symptoms may resemble those of obstructive epicardial coronary disease or vasospastic angina…

…pupillary reflex. Importantly, pupillary size and reactivity are influenced by factors beyond neural activity. Systemic catecholamines released or administered during resuscitation can affect pupil to

…necrosis and cardiac troponin release meeting the criteria of the universal definition of MI. Clinically, UA is defined by one or more of the following…

…Modified release preparations, anticholinergics, opioids and salicylate — where gastric emptying is delayed — may justify charcoal later, in some cases up to 6 hours or more…

…a dialysis patient, in severe acute kidney injury, in treatment failure or in ongoing massive potassium release. In cardiac arrest with suspected hyperkalaemia, advanced life…

…when a modified release preparation is started in an opioid naive patient, or when a conversion between drugs is made without reduction for incomplete cross…

…estimated quantity the time, and whether the intake was single or repeated a modified release preparation or a combination product concurrent drugs, alcohol and illicit…

…troponin release that does not fulfil the criteria for ischaemic myocardial infarction. It may be acute, when serial troponin values show a dynamic change, or…